financetom
Business
financetom
/
Business
/
BRIEF-Topbuild To Acquire Progressive Roofing In All-Cash Transaction Valued At $810 Million
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Topbuild To Acquire Progressive Roofing In All-Cash Transaction Valued At $810 Million
Jul 8, 2025 4:16 AM

July 8 (Reuters) - TopBuild Corp ( BLD ):

* TOPBUILD TO ACQUIRE PROGRESSIVE ROOFING IN ALL-CASH

TRANSACTION

VALUED AT $810 MILLION, CREATING A NEW GROWTH PLATFORM

* TOPBUILD CORP ( BLD ) - DEAL EXPECTED TO BE ACCRETIVE TO ADJUSTED

EPS

* TOPBUILD CORP ( BLD ) - DEAL FUNDED BY CREDIT FACILITY, EXPECTED

TO

CLOSE Q3 2025

Source text:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Helmerich & Payne CFO Kevin Vann to Retire; Todd Scruggs Named Successor
Helmerich & Payne CFO Kevin Vann to Retire; Todd Scruggs Named Successor
Mar 16, 2026
07:15 AM EDT, 03/16/2026 (MT Newswires) -- Helmerich & Payne (HP) said Monday that Chief Financial Officer Kevin Vann will retire on June 30. Todd Scruggs, vice president of corporate finance and treasury, was named Vann's successor, effective July 1, the company said. Vann will continue serving as a senior adviser through Dec. 31, Helmerich & Payne added. ...
Form 8.3
Form 8.3
Mar 16, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Monte Rosa Therapeutics Signs Supply Deal With Johnson & Johnson for Phase 2 Prostate Cancer Study
Monte Rosa Therapeutics Signs Supply Deal With Johnson & Johnson for Phase 2 Prostate Cancer Study
Mar 16, 2026
08:13 AM EDT, 03/16/2026 (MT Newswires) -- Monte Rosa Therapeutics ( GLUE ) said Monday it has entered a clinical supply agreement with Johnson & Johnson ( JNJ ) to evaluate investigational drug MRT-2359 in combination with Erleada in patients with metastatic castration-resistant prostate cancer with androgen receptor mutations. Under the agreement, Monte Rosa Therapeutics ( GLUE ) will sponsor...
Form 8.3
Form 8.3
Mar 16, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved